Alerta

ENVELOPED VIRUS LIKE PARTICLES COMRISING SARS-COV-2 S PROTEIN

Resumen de: US20260014249A1

Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.

SYNTHESIS METHOD AND APPLICATION OF BENZOTHIASELENAZOLE-1-OXIDE COMPOUND AND DERIVATIVE THEREOF

Resumen de: US20260015332A1

The present invention discloses the synthetic methods and the corresponding applications of a benzothiaselenazole-1-oxide compound and derivatives thereof, in which with sulfoximine and elemental selenium as starting materials, a series of benzothiaselenazole-1-oxide compounds has been synthesized through rhodium-catalyzed direct C—H functionalization reaction. Furthermore, with sulfoximine and elemental selenium as starting materials, a chiral benzothiaselenazole-1-oxide compound is synthesized through direct C—H functionalization reaction by virtue of a chiral phosphoric acid ligand. The present invention can allow specific labeling of sulfydryl structures in polypeptides, carbohydrates, drug molecules, and proteins, as well as in proteins and other biomacromolecules, exhibiting good anti-SARS-CoV-2 activity; and a bioconjugate with trastuzumab according to the present invention can effectively image HER2 receptors on the cell surface and show intense fluorescence, and is applicable to the preparation of an imaging reagent for the HER2 receptors on the cell surface.

COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION

Resumen de: US20260015337A1

The present invention is generally directed to inhibitors of SARS-CoV-2-related 3C-like protease (Mpro) useful in the treatment of coronavirus infection and having the Formula (A):

RECOMBINANT POLYCLONAL PROTEINS TARGETING COVID-19 AND METHODS OF USE THEREOF

Resumen de: US20260015770A1

Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.

REAGENT FOR DETECTING SARS-RELATED CORONAVIRUS

Resumen de: US20260016473A1

The present invention relates to a compound represented by the following general formula (1), or a salt or solvate thereof:in the formula (1), R1, R2, and R3 are as defined in the description.

SARS-COV-2 VACCINE BOOSTER COMPOSITION

Resumen de: US20260014247A1

The present disclosure provides a composition for inducing or maintaining an immune response against SARS-COV-2 virus.

FORMULATIONS COMPRISING STABILIZED SARS-COV-2 PEPTIDES AND USES THEREOF

Resumen de: WO2024187120A1

Disclosed herein are dry powders, anhydrous compositions, and emulsions comprising a peptide that binds to a SARS-CoV-2 spike protein. The dry powders, anhydrous compositions, and emulsions disclosed herein are useful for the treatment and/or prevention of a coronavirus infection.

NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE

Resumen de: AU2024231716A1

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation.

NOVEL CORONAVIRUS PROTECTIVE NASAL SPRAY, AND PREPARATION AND USE THEREOF

Resumen de: EP4678663A1

A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.

COMBINATION THERAPIES COMPRISING STABILIZED SARS-COV-2 PEPTIDES

Nº publicación: EP4676940A1 14/01/2026

Solicitante:

RED QUEEN THERAPEUTICS INC [US]
DANA FARBER CANCER INST INC [US]
Red Queen Therapeutics, Inc,
Dana-Farber Cancer Institute, Inc

Resumen de: WO2024187121A1

Disclosed herein are methods of treating and/or preventing a coronavirus infection using a peptide that binds to a SARS-CoV-2 spike protein and an additional therapeutic agent. Also provided herein are therapeutic combinations comprising a peptide that binds to a SARS-CoV-2 spike protein and an additional therapeutic agent.